Literature DB >> 17668247

Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity.

Michael R Bendel-Stenzel1, Julia Steinke, Ranjan Dohil, Youngki Kim.   

Abstract

Nephropathic cystinosis is a lysosomal storage disorder, which, if untreated, results in renal failure by age 10 years. Oral cysteamine has been shown to preserve renal function in these patients. In this study, a 2-year-old girl with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl). This is only the second report of long-term i.v. cysteamine therapy for nephropathic cystinosis. Unlike the treatment in the previous case, however, treatment in our patient was limited by liver toxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17668247     DOI: 10.1007/s00467-007-0529-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  20 in total

Review 1.  First NIH/Office of Rare Diseases Conference on Cystinosis: past, present, and future.

Authors:  Robert Kleta; Frederick Kaskel; Ranjan Dohil; Paul Goodyer; Lisa M Guay-Woodford; Erik Harms; Julie R Ingelfinger; Vera H Koch; Craig B Langman; Mary B Leonard; Roslyn B Mannon; Minnie Sarwal; Jerry A Schneider; Flemming Skovby; Barbara C Sonies; Jess G Thoene; Doris A Trauner; William A Gahl
Journal:  Pediatr Nephrol       Date:  2005-01-27       Impact factor: 3.714

2.  Nephropathic cystinosis.

Authors:  W A Gahl
Journal:  Pediatr Rev       Date:  1997-09

3.  Veno-occlusive disease of the liver associated with cysteamine treatment of nephropathic cystinosis.

Authors:  E D Avner; D Ellis; R Jaffe
Journal:  J Pediatr       Date:  1983-05       Impact factor: 4.406

4.  Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants.

Authors:  A Pollak; M Hayde; M Hayn; K Herkner; K A Lombard; G Lubec; M Weninger; J A Widness
Journal:  Pediatrics       Date:  2001-01       Impact factor: 7.124

5.  Understanding intestinal cysteamine bitartrate absorption.

Authors:  Ranjan Dohil; Meredith Fidler; Bruce A Barshop; Jon Gangoiti; Reena Deutsch; Michael Martin; Jerry A Schneider
Journal:  J Pediatr       Date:  2006-06       Impact factor: 4.406

6.  Mechanisms for the cytotoxicity of cysteamine.

Authors:  T M Jeitner; D A Lawrence
Journal:  Toxicol Sci       Date:  2001-09       Impact factor: 4.849

Review 7.  Pharmacological treatment of nephropathic cystinosis with cysteamine.

Authors:  Robert Kleta; William A Gahl
Journal:  Expert Opin Pharmacother       Date:  2004-11       Impact factor: 3.889

8.  Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.

Authors:  Amy Barton Pai; Alex V Boyd; Charles R McQuade; Antonia Harford; Jeffrey P Norenberg; Philip G Zager
Journal:  Pharmacotherapy       Date:  2007-03       Impact factor: 4.705

9.  The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine.

Authors:  Ranjan Dohil; Robert O Newbury; Zachary M Sellers; Reena Deutsch; Jerry A Schneider
Journal:  J Pediatr       Date:  2003-08       Impact factor: 4.406

10.  Feeding problems in cystinosis.

Authors:  E Elenberg; L L Norling; R E Kleinman; J R Ingelfinger
Journal:  Pediatr Nephrol       Date:  1998-06       Impact factor: 3.714

View more
  1 in total

1.  In vitro activity of cysteamine against SARS-CoV-2 variants.

Authors:  Jess Thoene; Robert F Gavin; Aaron Towne; Lauren Wattay; Maria Grazia Ferrari; Jennifer Navarrete; Ranajit Pal
Journal:  Mol Genet Metab       Date:  2022-09-05       Impact factor: 4.204

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.